Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180986 | 1.00 | IDO1 (0.32) | IDO1CYP11B2CYP17A1 | |
| SCHEMBL1181258 | 1.00 | IDO1 (0.32) | IDO1CYP11B2CYP17A1 | |
| SCHEMBL14218860 | 0.73 | — | — | |
| SCHEMBL19659125 | 0.71 | PIK3CD (0.33) | — | |
| SCHEMBL14249072 | 0.69 | ACHE (0.36) | — | |
| SCHEMBL947045 | 0.67 | — | — | |
| SCHEMBL21265505 | 0.67 | IDO1 (0.33) | IDO1 | |
| SCHEMBL14249217 | 0.67 | — | — | |
| SCHEMBL4726645 | 0.66 | — | — | |
| SCHEMBL1180242 | 0.64 | CYP1A2 (0.38) | IDO1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8008334-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | HEROLD PETER | 2011-02-03 | — | — | US | disclosed |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| EP-1957489-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007065942-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | CYP11B1, CYP11B2, REN | IDO1 2723/4885CYP11B2 2/4885CYP17A1 10/4885 |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | REN, CYP11B1, CYP11B2 | IDO1 2549/4885CYP11B2 3/4885CYP17A1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.